<code id='6F16E13E98'></code><style id='6F16E13E98'></style>
    • <acronym id='6F16E13E98'></acronym>
      <center id='6F16E13E98'><center id='6F16E13E98'><tfoot id='6F16E13E98'></tfoot></center><abbr id='6F16E13E98'><dir id='6F16E13E98'><tfoot id='6F16E13E98'></tfoot><noframes id='6F16E13E98'>

    • <optgroup id='6F16E13E98'><strike id='6F16E13E98'><sup id='6F16E13E98'></sup></strike><code id='6F16E13E98'></code></optgroup>
        1. <b id='6F16E13E98'><label id='6F16E13E98'><select id='6F16E13E98'><dt id='6F16E13E98'><span id='6F16E13E98'></span></dt></select></label></b><u id='6F16E13E98'></u>
          <i id='6F16E13E98'><strike id='6F16E13E98'><tt id='6F16E13E98'><pre id='6F16E13E98'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:comprehensive    Page View:5
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In